Metastatic spinal cord compression: a validated survival score for elderly patients
Standard
Metastatic spinal cord compression: a validated survival score for elderly patients. / Rades, Dirk; Evers, Jasmin N; Bajrovic, Amira; Veninga, Theo; Karstens, Johann H; Schild, Steven E.
in: STRAHLENTHER ONKOL, Jahrgang 190, Nr. 10, 10.2014, S. 919-24.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Metastatic spinal cord compression: a validated survival score for elderly patients
AU - Rades, Dirk
AU - Evers, Jasmin N
AU - Bajrovic, Amira
AU - Veninga, Theo
AU - Karstens, Johann H
AU - Schild, Steven E
PY - 2014/10
Y1 - 2014/10
N2 - BACKGROUND AND PURPOSE: This study aimed to develop a validated survival score for elderly patients with metastatic spinal cord compression (MSCC).PATIENTS AND METHODS: In all, 1,128 patients were randomly assigned to the test (n = 564) or validation group (n = 564). In the test group, ten pretreatment factors (age, gender, performance status, primary tumor, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time to developing motor deficits) plus the radiation regimen were retrospectively evaluated. Factors significantly associated with survival on multivariate analysis were included in the survival score. The score for each factor was determined by dividing the 6-month survival rate (%) by 10. The prognostic score represented the sum of the scores for each factor.RESULTS: In the multivariate analysis of the test group, age, performance status, primary tumor type, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, and time to developing motor deficits were significantly associated with survival. Total scores ranged from 25 to 57 points. In the test group, 6-month survival rates were 11 % for 25-39 points, 56 % for 40-48 points, and 97 % for 49-57 points (p < 0.001). In the validation group, 6-month survival rates were 10, 53, and 94 %, respectively (p < 0.001).CONCLUSION: Based on the survival scores of the test group, three prognostic groups were identified. The survival rates of the validation group were similar to the test group. This score appears reproducible and can help select the appropriate treatment for elderly patients with MSCC.
AB - BACKGROUND AND PURPOSE: This study aimed to develop a validated survival score for elderly patients with metastatic spinal cord compression (MSCC).PATIENTS AND METHODS: In all, 1,128 patients were randomly assigned to the test (n = 564) or validation group (n = 564). In the test group, ten pretreatment factors (age, gender, performance status, primary tumor, number of involved vertebrae, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, time to developing motor deficits) plus the radiation regimen were retrospectively evaluated. Factors significantly associated with survival on multivariate analysis were included in the survival score. The score for each factor was determined by dividing the 6-month survival rate (%) by 10. The prognostic score represented the sum of the scores for each factor.RESULTS: In the multivariate analysis of the test group, age, performance status, primary tumor type, ambulatory status, other bone metastases, visceral metastases, interval from cancer diagnosis to radiotherapy of MSCC, and time to developing motor deficits were significantly associated with survival. Total scores ranged from 25 to 57 points. In the test group, 6-month survival rates were 11 % for 25-39 points, 56 % for 40-48 points, and 97 % for 49-57 points (p < 0.001). In the validation group, 6-month survival rates were 10, 53, and 94 %, respectively (p < 0.001).CONCLUSION: Based on the survival scores of the test group, three prognostic groups were identified. The survival rates of the validation group were similar to the test group. This score appears reproducible and can help select the appropriate treatment for elderly patients with MSCC.
KW - Age Distribution
KW - Aged
KW - Aged, 80 and over
KW - Carcinoma
KW - Causality
KW - Female
KW - Geriatric Assessment
KW - Germany
KW - Humans
KW - Incidence
KW - Male
KW - Prognosis
KW - Proportional Hazards Models
KW - Radiotherapy, Conformal
KW - Reproducibility of Results
KW - Risk Assessment
KW - Sensitivity and Specificity
KW - Spinal Cord Compression
KW - Spinal Cord Neoplasms
KW - Survival Analysis
KW - Treatment Outcome
U2 - 10.1007/s00066-014-0641-1
DO - 10.1007/s00066-014-0641-1
M3 - SCORING: Journal article
C2 - 24658606
VL - 190
SP - 919
EP - 924
JO - STRAHLENTHER ONKOL
JF - STRAHLENTHER ONKOL
SN - 0179-7158
IS - 10
ER -